Article of the day, September 5th, suggested by the Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn:

“Article of the day! Suggest by the Immune Oncology Research Institute.

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

Authors: Nicoletta Colombo, Elena Biagioli, Kenichi Harano, Francesca Galli, Emma Hudson, Yoland Antill, Chel Hun Choi, Manuela Rabaglio, Frederic Marmé, Christian Marth, Gabriella Parma, Lorena Fariñas-Madrid, Shin Nishio, Karen Allan, Yeh Chen Lee, Elisa Piovano, Beatriz Pardo, Satoshi Nakagawa, John McQueen, Claudio Zamagni, Luis Manso, Kazuhiro Takehara, Giulia Tasca, Annamaria Ferrero, Germana Tognon, Andrea Alberto Lissoni, Mariacristina Petrella, Maria Elena Laudani, Eliana Rulli, Sara Uggeri, M Pilar Barretina Ginesta and AtTEnd study group.

Author Affiliations: European School of Oncology, IDeA Lab Università degli Studi di Milano Bicocca,Velindre Cancer Centre, Peninsula Health,Samsung Medical Center, Ferdinando Cerciello, Vall d’Hebron Institute of Oncology (VHIO), Kurume University, NHMRC Clinical Trials Centre, IRCCS Istituto Ortopedico Rizzoli,Hospital 12 de Octubre, Azienda Ospedaliero-Universitaria Careggi,et al.

Source: Immune Oncology Research Institute/LinkedIn

Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.

Other posts featuring Immune Oncology Research Institute on OncoDaily.